What pharmacologic treatments are recommended for managing fentanyl (opioid) and methamphetamine withdrawal?

Management of Methamphetamine and Fentanyl Withdrawal

For fentanyl (opioid) withdrawal, start buprenorphine 4-8 mg sublingual when the patient shows moderate-to-severe withdrawal symptoms (COWS >8), targeting 16 mg total on day one; for methamphetamine withdrawal, there are no FDA-approved medications, but supportive care with symptom management is the standard approach. 111

Fentanyl/Opioid Withdrawal Management

Assessment and Timing

Before initiating treatment, confirm time since last opioid use:

• Short-acting opioids (heroin, fentanyl): >12 hours
• Extended-release formulations: >24 hours
• Methadone maintenance patients: >72 hours 1

Critical caveat: With fentanyl-contaminated drugs becoming ubiquitous, precipitated withdrawal can occur even when patients appear to be in adequate withdrawal. If precipitated withdrawal occurs, rapidly escalate buprenorphine to high doses (up to 20 mg) rather than stopping—this will reverse the precipitated withdrawal 2.

Buprenorphine Protocol (First-Line)

For moderate-to-severe withdrawal (COWS ≥8):

• Give buprenorphine 4-8 mg sublingual based on severity
• Reassess after 30-60 minutes
• Target 16 mg total on day one for most patients
• Continue 16 mg daily thereafter 11

For mild withdrawal (COWS <8):

• No buprenorphine indicated initially
• Reassess in 1-2 hours
• Initiate when withdrawal progresses 1

Evidence strength: Buprenorphine demonstrates superior efficacy compared to clonidine/lofexidine with less severe withdrawal symptoms, fewer adverse effects, and better treatment retention. It performs similarly to methadone for withdrawal management 11.

Alternative: Methadone

Methadone can be administered for up to 72 hours without special program enrollment, but its long duration of action (hours to days) and potential interference with ongoing treatment programs make it less commonly used in acute settings 11.

Non-Opioid Adjunctive Medications

For symptomatic relief, use combination therapy:

• α2-agonists: Clonidine or lofexidine for autonomic symptoms (avoid if hypotensive)
• Antiemetics: Promethazine for nausea/vomiting
• Benzodiazepines: For muscle cramps, anxiety, and catecholamine release
• Antidiarrheals: Loperamide for diarrhea 111

These medications treat symptoms but do NOT reduce relapse risk or improve long-term outcomes like buprenorphine does.

Methamphetamine Withdrawal Management

Evidence Reality Check

There is no FDA-approved medication for methamphetamine withdrawal, and the evidence quality is very low 3. A 2023 systematic review found insufficient evidence to recommend any specific medication 3.

Supportive Care Approach

Medications with weak evidence that may help in light-to-moderate users:

• Mirtazapine: Shows potential benefit during acute and protracted withdrawal phases 45
• Bupropion: Some evidence for early recovery 45
• Naltrexone (long-acting): May benefit light-to-moderate users 5

Practical management focuses on:

• Sleep disturbances (consider trazodone or mirtazapine)
• Depression and anhedonia (monitor, consider antidepressants)
• Anxiety (benzodiazepines short-term if needed)
• Psychosis if present (antipsychotics)

Critical Safety Issue

Methamphetamine is increasingly adulterated with fentanyl 5. All patients using methamphetamine should:

• Receive naloxone kits for overdose prevention
• Be counseled about fentanyl contamination risk
• Be screened for concurrent opioid use 5

Polysubstance Withdrawal (Both Drugs)

When managing concurrent methamphetamine and fentanyl withdrawal:

1. Prioritize the opioid withdrawal with buprenorphine as outlined above—opioid withdrawal has established effective treatment 11
2. Layer symptomatic management for methamphetamine withdrawal symptoms
3. Use α2-agonists cautiously—they help both opioid and stimulant withdrawal but monitor for hypotension 6
4. Address psychiatric symptoms aggressively (depression, anxiety, psychosis)

Discharge Planning Essentials

If prescriber has X-waiver (or under new 2023 rules, any DEA-licensed prescriber):

• Prescribe buprenorphine/naloxone 16 mg daily for 3-7 days until follow-up
• Ensure confirmed outpatient addiction treatment appointment 11

If no waiver/unable to prescribe:

• Patient may return for up to 3 consecutive days for administration only
• Must arrange referral for ongoing treatment 11

Always provide:

• Naloxone kit with overdose education
• Hepatitis C and HIV screening
• Harm reduction counseling 1

Key Pitfalls to Avoid

1. Don't wait too long to start buprenorphine—with fentanyl, traditional timing may need adjustment; consider low-dose induction ("microdosing") if concerned about precipitated withdrawal 27

2. Don't use opioid detoxification alone—it's associated with relapse and poor outcomes. Always initiate maintenance treatment with buprenorphine or methadone 8

3. Don't assume methamphetamine withdrawal is benign—while not life-threatening like alcohol/benzodiazepine withdrawal, it causes significant distress and increases relapse risk 34

4. Don't forget fentanyl contamination—even patients who think they're only using methamphetamine may have opioid exposure 5